Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11β-hydroxysteroid dehydrogenase
Open Access
- 8 August 2011
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 108 (33) , 13722-13727
Abstract
Corticotropin-releasing hormone (CRH) and growth hormone-releasing hormone (GHRH), primarily characterized as neuroregulators of the hypothalamic-pituitary-adrenal axis, directly influence tissue-specific receptor-systems for CRH and GHRH in the endocrine pancreas. Here, we demonstrate the expression of mRNA for CRH and CRH-receptor type 1 (CRHR1) and of protein for CRHR1 in rat and human pancreatic islets and rat insulinoma cells. Activation of CRHR1 and GHRH-receptor significantly increased cell proliferation and reduced cell apoptosis. CRH stimulated both cellular content and release of insulin in rat islet and insulinoma cells. At the ultrastructural level, CRHR1 stimulation revealed a more active metabolic state with enlarged mitochondria. Moreover, glucocorticoids that promote glucose production are balanced by both 11b-hydroxysteroid dehydrogenase (11β-HSD) isoforms; 11β-HSD–type-1 and 11β-HSD–type-2. We demonstrated expression of mRNA for 11β-HSD-1 and 11β-HSD-2 and protein for 11β-HSD-1 in rat and human pancreatic islets and insulinoma cells. Quantitative real-time PCR revealed that stimulation of CRHR1 and GHRH-receptor affects the metabolism of insulinoma cells by down-regulating 11β-HSD-1 and up-regulating 11β-HSD-2. The 11β-HSD enzyme activity was analyzed by measuring the production of cortisol from cortisone. Similarly, activation of CRHR1 resulted in reduced cortisol levels, indicating either decreased 11β-HSD-1 enzyme activity or increased 11β-HSD-2 enzyme activity; thus, activation of CRHR1 alters the glucocorticoid balance toward the inactive form. These data indicate that functional receptor systems for hypothalamic-releasing hormone agonists exist within the endocrine pancreas and influence synthesis of insulin and the pancreatic glucocorticoid shuttle. Agonists of CRHR1 and GHRH-receptor, therefore, may play an important role as novel therapeutic tools in the treatment of diabetes mellitus.Keywords
This publication has 32 references indexed in Scilit:
- Glucocorticoids Differentially Regulate the Expression of CRFR1 and CRFR2α in MIN6 Insulinoma Cells and Rodent IsletsEndocrinology, 2011
- Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic isletsProceedings of the National Academy of Sciences, 2010
- Regulatory mechanism of hypothalamo-pituitary–adrenal (HPA) axis and neuronal changes after adrenalectomy in type 2 diabetesJournal of Chemical Neuroanatomy, 2010
- CRFR1 is expressed on pancreatic β cells, promotes β cell proliferation, and potentiates insulin secretion in a glucose-dependent mannerProceedings of the National Academy of Sciences, 2009
- Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic β-cellsJournal of Endocrinology, 2008
- Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic β-cellsPeptides, 2006
- Increased expression and activity of 11β-HSD-1 in diabetic islets and prevention with troglitazoneBiochemical and Biophysical Research Communications, 2004
- Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid needNature, 1995
- Stress and Diabetes MellitusDiabetes Care, 1992
- Receptor-mediated immunomodulation by corticotropin-releasing factorCellular Immunology, 1991